Cargando…
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study
BACKGROUND: Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a f...
Autores principales: | Menzies-Gow, Andrew, Gurnell, Mark, Heaney, Liam G., Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Harrison, Timothy, Jackson, David J., Price, David, Lugogo, Njira, Kreindler, James, Burden, Annie, de Giorgio-Miller, Alex, Faison, Sarai, Padilla, Kelly, Martin, Ubaldo J., Garcia Gil, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791910/ https://www.ncbi.nlm.nih.gov/pubmed/35896216 http://dx.doi.org/10.1183/13993003.03226-2021 |
Ejemplares similares
-
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019) -
Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma
por: Gurnell, M., et al.
Publicado: (2021) -
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
por: Menzies-Gow, Andrew, et al.
Publicado: (2022) -
A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
por: Menzies-Gow, Andrew, et al.
Publicado: (2022) -
Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)